News & Events

Redbiotec is pleased to announce that it has entered into a collaboration with 4-Antibody, in which Redbiotec will apply its proprietary technology platform rePAX® to an undisclosed discovery area. This agreement is a further validation of the application of Redbiotec’s VLPs in antibody generation.

Prof. Polly Roy, scientific advisor to Redbiotec in the field of VLPs and antibodies for infectious diseases and cancer, has been awarded with one of India’s most prestigious academic awards “The General President’s Gold Medal” in recognition of her work in the field of viruses. Professor Roy received the medal at the 99th Indian Science Congress held at the Kalinga Institute of Industrial Technology (KIIT University) in Bhubaneswar, India, earlier this month. We are proud to have Polly on board of Redbiotec and congratulate her wholeheartedly to this achievement!

The German Cancer Research Institute (DKFZ) and Redbiotec have extended their collaboration in the field of HPV, which started in 2009. Goal of the collaboration is the validation of chimeric VLPs, containing proteins of different serotypes on one VLP.

For the proof-of-principle, influenza A/PR/8/34 VLPs carrying four parental proteins were tested in a mouse challenge model. Preliminary results show that Redbiotec’s influenza-VLPs effectively protect the immunized mice against the parental challenge virus. Please contact us for more information to these study results.

Redbiotec has entered into a cooperation with Intercell AG (Vienna, Austria), in which Redbiotec will apply its proprietary technology platform rePAX® to an undisclosed discovery area. This agreement is an additional step in Redbiotec’s successful partnering activities during 2011.

Redbiotec develops prophylactic vaccines in the area of CMV (Cytomegalovirus), HPV and Influenza and provides customized solutions in biologics.